The detection rate and variants of monoclonal gammopathy among patients in a multidisciplinary therapeutic hospital


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Oligosecretory monoclonal gammopathy is the result of the hyperproduction of a small proliferating cell clone, which, after various periods, can transform into overt secreting hematological tumors, but may be a cause of non-tumor organ and tissue damage, including kidney disease. The frequency, severity, and spectrum of monoclonal gammopathy in patients from different departments of a multidisciplinary therapeutic hospital have been studied. The nosological characteristics of diseases associated with monoclonal gamma of undetermined significance (MGUS) are given; special attention is paid to kidney diseases, including immune-mediated diseases, the association of which to MGUS has been least studied.

Full Text

Restricted Access

About the authors

N. Mrykhin

M. Sechenov First Moscow State Medical University (Sechenov University)

Email: natasha_tcheb@mail.ru
Moscow

L. Lysenko

M. Sechenov First Moscow State Medical University (Sechenov University)

Email: natasha_tcheb@mail.ru
Professor, MD Moscow

N. Chebotareva

M. Sechenov First Moscow State Medical University (Sechenov University)

Email: natasha_tcheb@mail.ru
Candidate of Medical Sciences Moscow

V. Rameev

M. Sechenov First Moscow State Medical University (Sechenov University)

Email: natasha_tcheb@mail.ru
Candidate of Medical Sciences Moscow

T. Androsova

M. Sechenov First Moscow State Medical University (Sechenov University)

Email: natasha_tcheb@mail.ru
Candidate of Medical Sciences Moscow

S. Roshchupkina

M. Sechenov First Moscow State Medical University (Sechenov University)

Email: natasha_tcheb@mail.ru
MrykhinProfessor L. Lysenko1, MD; N. Chebotareva1, Candidate of Medical Sciences; V.Rameev1, Candidate of Medical Sciences; T. Androsova’, Candidate of Medical Sciences; S. Roshchupkina1 ; £ Git el1. Candidate of Medical Sciences; I. Kogarkos, MD; S. Maryina2 Moscow

E. Gitel

M. Sechenov First Moscow State Medical University (Sechenov University)

Email: natasha_tcheb@mail.ru
Candidate of Medical Sciences Moscow

I. Kogarko

Semenov Institute of Chemical Physics Russian Academy of Sciences

Email: natasha_tcheb@mail.ru
MD Moscow

S. Maryina

National Medical Research Center of Flematology

Email: natasha_tcheb@mail.ru
Moscow

References

  1. Kyle R., Rajkumar S. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma // Curr. Hematol. Malig. Rep. - 2010; 5 (2): 62-9. doi: 10.1007/si 1899-010-0047-9.
  2. Zingone A., Kuehl M. Pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and progression to multiple myeloma // Semin Hematol. - 2011 ; 48 (1 ): 4-12. doi: 10.1053/j.seminhematol.2010.11.003.
  3. Merlini G., Palladini G. Differential diagnosis of monoclonal gam-mopathy of undetermined significance // Hematology. Am. Soc. Hematol. Educ. Program. -2012; 2012: 595-603. doi: 10.1182/asheduca-tion-2012.1.595.
  4. Knight G., Gao L., Gragnani L. et al. Detection of WA В cells in hepatitis С virus infection: a potential prognostic marker for cryo-globulinemic vasculitis and В cell malignancies // Arthr. Rheum. - 2010; 62: 2152-9. doi: 10.1002/art.27490.
  5. Gertz M. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management // Am. J. Hematol. - 2011; 86: 181-6. doi: 10.1002/ajh.21934.
  6. Debiec H., Hanoy M., Francois A. et al. Recurrent membranous nephropathy in an allograft caused by lgG3ic targeting the PLA2 receptor // J. Am. Soc. Nephrol. - 2012; 23 (12): 1949-54. doi: 10.1681/ASN.2012060577.
  7. Kapoulas S., Raptis V., Papaioannou M. New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies // Nephrol. Ther. - 2015; 11 (3): 135-43. doi: 10.1016/j.nephro.2014.12.005.
  8. Bridoux F., Leung N., Hutchison C. et al. Diagnosis of monoclonal gammopathy of renal significance // Kidney Int. - 2015; 87 (4): 698-711. doi: 10.1038/ki.2014.408.
  9. Kyle R., Therneau T., Rajkumar S. et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later // Mayo Clin. Proc. - 2004; 79 (7): 859-66. doi: 10.1016/S0025-6196(11 )62151 -4.
  10. Landgren 0., Kyle R., Pfeiffer R. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study // Blood. - 2009; 113: 5412-7. doi: 10.1182/blood-2008-12-194241.
  11. Landgren 0., Graubard B., Katzmann J. et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey // Leukemia. -2014; 28 (7): 1537-42. doi: 10.1038/leu.2014.34.
  12. Kyle R., Rajkumar S. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression // Br. J. Haematol. - 2007; 139 (5): 730-43. DOI: 10.1111 /j.1365-2141,2007.06873.x.
  13. Landgren O., Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes // J. Intern. Med. - 2017; 281 (4): 365-82. doi: 10.1111/joim.12590.
  14. Doyle L., Gundrum J., Farnen J. et al. Determining why and which clinicians order serum protein electrophoresis (SPEP), subsequent diagnoses based on indications, and clinical significance of routine follow-up: a study of patients with monoclonal gammopathy of undetermined significance (MGUS) // Blood. - 2009; 114 (22): 4883.
  15. Weiss B., Abadie J., Verma P. et al. A monoclonal gammopathy precedes multiple myeloma in most patients // Blood. - 2009; 113: 5418-22. DOI: 10.1182/ blood-2008-12-195008. выставка IPhEB 02-04 апреля 2019 Сан кт- Петербург
  16. Kyle R. Monoclonal gammopathy of undetermined significance: natural history in 241 cases // Am. J. Med. - 1978; 64: 814-26.
  17. Go R., Rajkumar S. How I manage monoclonal gammopathy of undetermined significance // Blood. - 2018; 131 (2): 163-73. doi: 10.1182/blood-2017-09-807560.
  18. Rajkumar S., Kyle R., Therneau T. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance // Blood. - 2005; 106: 812-7. doi: 10.1182/blood-2005-03-1038.
  19. Bida J., Kyle R., Therneau T. et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients // Mayo Clin. Proc. - 2009; 84 (8): 685-93. doi: 10.1016/S0025-6196(11)60518-1.
  20. Leung N., Bridoux F., Hutchison C. et al. International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant // Blood. -2012; 120 (22): 4292-5. DOI: 10.1182/ blood-2012-07-445304.
  21. Sethi S., Fervenza F., Rajkumar S. Spectrum of manifestations of monoclonal gammopathy-associated renal lesions // Curr. Opin. Nephrol. Hypertens. - 2016; 25:127-37. doi: 10.1097/MNH.0000000000000201.
  22. Steiner N., Göbel G., Suchecki P. et al. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients // Oncotarget. - 2017; 9 (2) : 2344-56. doi: 10.18632/oncotarget.23412.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies